StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
NASDAQ BLPH opened at $0.04 on Tuesday. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $0.10. The stock has a market cap of $440,388.00, a PE ratio of -0.04 and a beta of 0.70. The firm’s fifty day moving average price is $0.04 and its two-hundred day moving average price is $0.05.
Bellerophon Therapeutics Company Profile
Read More
- Five stocks we like better than Bellerophon Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- 3 Warren Buffett Stocks to Buy Now
- AMD Gains Momentum With AI: Can It Beat Expectations?
- What is a Secondary Public Offering? What Investors Need to Know
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.